## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%); PEG 3.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Piper Sandler Upgrades Colgate-Palmolive Company (CL) to Overweight**
- Source: StreetInsider | 20260107T101232 | Bullish | Relevance: 100%
- Piper Sandler analyst Michael Lavery upgraded Colgate-Palmolive Company (NYSE: CL) to Overweight. The article notes this is a premium article, with details available upon sign-in or upgrading to StreetInsider.com Premium.

**2. Did Colgate-Palmoliveâ€™s (CL) Dividend King Status and Q4 Preview Just Redefine Its Defensive Edge?**
- Source: Simply Wall Street | 20260106T182904 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive's status as a Dividend King and its focus on science-based innovation and cost initiatives are gaining attention ahead of its Q4 earnings. This reinforces its reputation as a defensive consumer staples leader, with new innovation and emerging market execution expected to influence its investment narrative. Despite strong dividend reliability and margin resilience, persistent consumer caution remains a key risk for volume growth.

**3. Colgate-Palmolive (CL) Remains Overweight as JPMorgan Sees Headwinds Easing in 2026**
- Source: Insider Monkey | 20260105T215800 | Somewhat-Bullish | Relevance: 100%
- JPMorgan has maintained its Overweight rating on Colgate-Palmolive (CL) and increased its price target to $88, anticipating an easing of economic headwinds in 2026. The firm notes that while 2025 presented challenges for household and personal care, improvements are expected as pressures like strain on low-income consumers and tariffs are lapped. Colgate-Palmolive, a "Dividend King" with 63 consecutive years of dividend increases, focuses on everyday essentials, innovation, and strategic pricing to maintain market position and manage costs.

**4. Piper Sandler Upgrades Colgate-Palmolive (CL) with 7.32% PT Incr**
- Source: GuruFocus | 20260107T133729 | Bullish | Relevance: 100%
- Piper Sandler has upgraded Colgate-Palmolive (CL) to "Overweight" from "Neutral," raising its price target by 7.32% to $88.00. This adjustment by analyst Michael Lavery signals a more optimistic outlook on the company's future performance. The new target suggests an upside of 13.29% from the current price, with the average analyst target being $87.46.

**5. Piper Sandler upgrades Colgate-Palmolive stock rating to Overweight**
- Source: Investing.com | 20260107T110940 | Bullish | Relevance: 100%
- Piper Sandler has upgraded Colgate-Palmolive (NYSE:CL) from Neutral to Overweight, raising its price target from $82.00 to $88.00, citing expectations for accelerated growth in 2026 driven by emerging markets and favorable currency trends. The firm's analysis suggests the stock, currently trading near its 52-week low, is undervalued and benefits from a diversified geographic exposure and strong gross profit margin. This upgrade contrasts with a recent downgrade by Argus due to margin pressures but aligns with an RBC Capital upgrade.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | Piper Sandler | $88 | $82 | +7% |
| 2025-12-18 | JP Morgan | $88 | $87 | +1% |
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | Piper Sandler | up | Overweight |
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.1x requires aggressive growth execution.
3. Long-term trend broken: trading 9.3% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.05 signals overvaluation risk, limited margin of safety. Forward P/E 20.1x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.3B |
| Beta | 0.30 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.05 |
| Forward P/E | 20.1 |
| Current P/E | 21.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.0% to -2.5% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.52% (CS: 18) | Weak |
| RSI_14 | 42.0 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.907x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.11
- **Stop Loss:** $74.67 (3.2% risk)
- **Target:** $79.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 204
- **Position Value:** $15,730.44
- **Portfolio %:** 15.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*